Back to results
US 2026/0216233 A1Published application
Compositions for the prevention and/or treatment of colonic group 3 innate lymphoid cells (ilc3)-mediated diseases and methods of using same
AssigneeDuke University
InventorsNeeraj Surana, Chin Yee Tan
Life of this patent
Estimating the term…
Abstract
The present disclosure describes, in part, compositions for the prevention and/or treatment of group 3 innate lymphoid cells (ILC3)-mediated diseases and methods of using same.
Claims81
A purified exopolysaccharide (EPS) isolated from Clostridium immunis (C. immunis), said EPS comprising a plurality of mannose and glucose subunits and a phosphocholine.
A pharmaceutical composition comprising a purified EPS as in any of the preceding claims and a pharmaceutically acceptable diluent, excipient and/or carrier.
A purified exopolysaccharide (EPS) from C. immunis isolated by the following steps:
- culturing medium inoculated with C. immunis;
- centrifuging the cultured medium to pellet the C. immunis;
- filtering the supernatant;
- treating the filtered supernatant with DNaseI and RNaseA;
- centrifuging the DNaseI and RNaseA treated supernatant to clarify;
- treating the clarified supernatant with proteinase;
- dialyzing the proteinase treated supernatant by adding ultrapure water and spinning through a spin column to eliminate the proteinase;
- and
- precipitating the proteinase-free and dialyzed remaining solution with ethanol.
6 more elements
Dependencies are inferred from the claim text.